Takeda Acquires Nimbus Therapeutics' TYK2 Program Subsidiary (Nimbus Lakshmi)
February 8, 2023
Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.
- Buyers
- Takeda Pharmaceutical Company Limited
- Targets
- Nimbus Lakshmi, Inc.
- Sellers
- Nimbus Therapeutics, LLC
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Dr. Reddy's Laboratories Acquires Nimbus Health GmbH
February 22, 2022
Pharmaceuticals
Dr. Reddy's Laboratories has entered into a definitive agreement to acquire German medical cannabis pioneer Nimbus Health GmbH. Nimbus, a licensed pharmaceutical wholesaler and manufacturer based in Frankfurt, will provide Dr. Reddy's with medical-cannabis manufacturing, importing and distribution capabilities to accelerate growth in Europe.
-
Takeda Pharmaceutical Company Limited Acquires Maverick Therapeutics, Inc.
March 9, 2021
Biotechnology
Takeda exercised its option to acquire Maverick Therapeutics, obtaining Maverick's COBRA conditionally active bispecific T‑cell engager platform and lead development candidates (TAK‑186 and TAK‑280). The deal, based on a prior collaboration and equity stake, is structured for up to $525 million in upfront and potential milestone payments and will fold Maverick's R&D team into Takeda's organization.
-
Kuraray Co., Ltd. Acquires Nelumbo Inc.
April 2, 2025
Manufacturing
Kuraray Co., Ltd. has acquired Nelumbo Inc., a Hayward, California-based developer of surface modification technologies, to add a new technology platform and accelerate global expansion. The deal—executed through Kuraray's U.S. subsidiary Kuraray Holdings U.S.A., Inc.—was announced April 2, 2025; the purchase price was not disclosed and Houlihan Lokey served as Nelumbo's exclusive financial advisor.
-
AbbVie Completes Acquisition of Nimble Therapeutics
January 23, 2025
Biotechnology
AbbVie has completed its acquisition of Nimble Therapeutics, adding Nimble's investigational oral peptide IL23R inhibitor for psoriasis and a peptide synthesis, screening and optimization platform to AbbVie's immunology pipeline. The deal is intended to strengthen AbbVie's R&D capabilities and accelerate discovery and optimization of oral peptide therapeutics.
-
Otsuka Pharmaceutical Acquires Jnana Therapeutics
August 1, 2024
Biotechnology
Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.
-
Eilean Therapeutics Acquires Ness Therapeutics
March 4, 2024
Biotechnology
Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.